TELA Stock Price, Tela Bio Inc Quote, Chart

Market Summary

USD4.45+0.06

Market Closed

1.37%

TELA Stock Price

View Fullscreen

TELA RSI Chart

TELA Valuation

Market Cap

109.7M

Price/Earnings (Trailing)

-2.35

Price/Sales (Trailing)

1.88

Price/Free Cashflow

-2.65

TELA Price/Sales (Trailing)

TELA Profitability

Return on Equity

-247.15%

Return on Assets

-59.79%

Free Cashflow Yield

-37.8%

TELA Fundamentals

TELA Revenue

Revenue (TTM)

58.5M

Rev. Growth (Yr)

46.26%

Rev. Growth (Qtr)

12.93%

TELA Earnings

Earnings (TTM)

-46.7M

Earnings Growth (Yr)

-29.17%

Earnings Growth (Qtr)

-17.64%

Breaking Down TELA Revenue

Last 7 days

-6.3%

Last 30 days

-20.7%

Last 90 days

-38.0%

Trailing 12 Months

-53.1%

How does TELA drawdown profile look like?

TELA Financial Health

Current Ratio

4.23

Debt/Equity

2.15

Debt/Cashflow

-1.01

TELA Investor Care

Shares Dilution (1Y)

27.82%

Diluted EPS (TTM)

-2.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	45.1M	49.2M	53.1M	58.5M
2022	31.8M	34.7M	38.2M	41.4M
2021	20.4M	24.4M	26.8M	29.5M
2020	15.9M	16.1M	17.4M	18.2M
2019	10.1M	11.9M	13.7M	15.4M
2018	0	0	6.3M	8.3M
2017	0	0	0	4.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tela Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	talmo paul	sold (taxes)	-1,077	5.67	-190	chief technology officer
Mar 31, 2024	firestone gregory a.	sold (taxes)	-674	5.67	-119	chief business officer
Mar 31, 2024	murphy peter c.	sold (taxes)	-924	5.67	-163	chief commercial officer
Mar 31, 2024	koblish antony	sold (taxes)	-2,182	5.67	-385	chief executive officer
Mar 31, 2024	smeykal megan	sold (taxes)	-544	5.67	-96.00	chief accounting officer
Feb 24, 2024	smeykal megan	sold (taxes)	-3,810	7.07	-539	chief accounting officer
Feb 24, 2024	murphy peter c.	sold (taxes)	-6,645	7.07	-940	chief commercial officer
Feb 24, 2024	talmo paul	sold (taxes)	-7,416	7.07	-1,049	chief technology officer
Feb 24, 2024	koblish antony	sold (taxes)	-40,482	7.07	-5,726	chief executive officer
Feb 24, 2024	firestone gregory a.	sold (taxes)	-1,696	7.07	-240	chief business officer

Which funds bought or sold TELA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-12.63	-80,826	240,323	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-9,000	-	-%
Apr 23, 2024	BFSG, LLC	new	-	2,977	2,977	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.19	-12,000	3,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-67,736	-	-%
Apr 05, 2024	CWM, LLC	new	-	2,000	2,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-73,985	354,911	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.34	-1,195,620	6,612,410	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	-11,363	53,245	-%
Feb 16, 2024	Spouting Rock Asset Management, LLC	reduced	-12.1	-46,891	125,085	0.05%

Are Funds Buying or Selling TELA?

Are funds buying TELA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TELA

No. of Funds

Unveiling Tela Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	10.47%	2,564,028	SC 13G
Feb 14, 2024	ew healthcare partners fund 2, l.p.	6.60%	1,615,368	SC 13G
Feb 07, 2024	hirschman orin	5.6%	1,377,945	SC 13G/A
Oct 06, 2023	first light asset management, llc	10.33%	2,528,600	SC 13G
Apr 21, 2023	orbimed advisors llc	11.9%	2,866,267	SC 13D/A
Feb 15, 2023	hirschman orin	8.7%	1,679,281	SC 13G/A
Feb 14, 2023	rtw investments, lp	2.0%	390,364	SC 13G/A
Aug 24, 2022	hirschman orin	7.9%	1,517,992	SC 13G
Aug 22, 2022	ew healthcare partners fund 2, l.p.	8.51%	1,630,994	SC 13D/A
Aug 19, 2022	orbimed advisors llc	16.5%	3,058,267	SC 13D/A

Recent SEC filings of Tela Bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 15, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 22, 2024	10-K	Annual Report

Peers (Alternatives to Tela Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

Tela Bio Inc News

Latest updates

Tela Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	12.9%	16,998	15,052	14,494	11,909	11,622	11,159	10,406	8,231	8,374	7,654	7,558	5,877	5,667	5,313	3,507	3,726	4,864	3,973	3,303	3,306	2,759
Gross Profit	11.9%	11,624	10,389	10,201	7,898	8,176	7,319	6,550	4,999	5,659	4,602	5,087	3,465	3,662	3,287	2,085	2,200	2,963	2,604	1,907	1,798	-
Operating Expenses	16.2%	23,902	20,570	20,563	19,152	17,615	16,806	16,787	14,843	13,313	11,819	12,398	10,734	10,409	10,150	7,251	8,699	8,789	6,460	6,207	6,978	-
S&GA Expenses	18.6%	17,164	14,474	14,577	13,466	11,647	11,172	11,055	9,378	8,313	6,948	7,502	6,299	6,377	6,342	4,123	5,269	5,382	4,736	3,947	3,995	-
R&D Expenses	13.4%	2,685	2,368	2,514	2,052	2,726	2,102	2,102	2,007	1,725	1,409	1,930	1,679	1,163	1,201	979	912	921	516	1,055	1,659	-
Interest Expenses	0.8%	1,345	1,334	1,298	1,246	1,174	1,032	934	911	922	922	864	889	903	898	884	879	884	899	914	912	-
Net Income	-17.6%	-12,890	-10,957	-10,790	-12,027	-9,979	-10,714	-12,741	-10,862	-8,619	-8,266	-8,255	-8,136	-7,790	-7,703	-6,081	-7,220	-6,532	-4,666	-5,261	-5,966	-
Net Income Margin	3.2%	-0.80*	-0.82*	-0.88*	-1.01*	-1.07*	-1.12*	-1.17*	-1.13*	-1.13*	-1.21*	-1.31*	-1.46*	-1.58*	-	-	-	-	-	-	-	-
Free Cashflow	-58.5%	-11,256	-7,102	-11,421	-11,689	-11,029	-7,939	-11,886	-10,766	-9,877	-6,921	-5,654	-8,607	-7,142	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-10.6%	78.00	87.00	94.00	59.00	68.00	80.00	51.00	55.00	63.00	69.00	74.00	78.00	86.00	92.00	98.00	59.00	68.00	23.00	27.00
Current Assets	-12.8%	72.00	82.00	89.00	54.00	62.00	74.00	46.00	50.00	59.00	66.00	71.00	75.00	83.00	89.00	94.00	55.00	64.00	18.00	23.00
Cash Equivalents	-19.7%	47.00	58.00	65.00	30.00	42.00	54.00	28.00	33.00	44.00	54.00	60.00	66.00	74.00	81.00	85.00	41.00	45.00	11.00	17.00
Inventory	-8.1%	13.00	14.00	14.00	15.00	12.00	12.00	10.00	10.00	8.00	6.00	5.00	5.00	4.00	4.00	5.00	5.00	5.00	4.00	4.00
Net PPE	13.4%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	4.2%	59.00	57.00	54.00	56.00	54.00	56.00	53.00	45.00	42.00	41.00	39.00	37.00	37.00	36.00	34.00	35.00	37.00	38.00	41.00
Current Liabilities	10.6%	17.00	15.00	13.00	14.00	12.00	15.00	12.00	12.00	11.00	9.00	7.00	6.00	7.00	5.00	4.00	4.00	7.00	6.00	10.00
Long Term Debt	0.4%	41.00	40.00	40.00	40.00	40.00	40.00	40.00	32.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	30.00	30.00	-	-
LT Debt, Non Current	0.4%	41.00	40.00	40.00	40.00	40.00	40.00	40.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-38.2%	19.00	31.00	40.00	3.00	14.00	23.00	-	10.00	20.00	28.00	35.00	42.00	49.00	56.00	63.00	24.00	31.00	-	-
Retained Earnings	-4.2%	-320	-308	-297	-286	-274	-264	-253	-240	-229	-221	-213	-204	-196	-188	-181	-175	-167	-160	-137
Additional Paid-In Capital	0.4%	340	338	337	289	288	287	252	251	250	249	248	247	246	245	245	199	199	-	-
Shares Outstanding	0.0%	24.00	24.00	24.00	19.00	19.00	17.00	15.00	15.00	14.00	14.00	14.00	14.00	13.00	-	-	-	-	-	-
Float	-	-	-	245	-	-	-	54.00	-	-	-	154	-	-	-	104	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-58.6%	-11,051	-6,968	-11,264	-11,574	-10,983	-7,649	-11,686	-10,430	-9,588	-6,630	-5,629	-8,585	-7,104	-3,690	-6,355	-7,307	-7,184	-5,357	-5,205	-7,777	-
Share Based Compensation	-9.3%	1,241	1,369	1,294	1,128	1,039	1,027	1,022	901	822	733	1,412	694	572	543	494	449	274	64.00	59.00	60.00	-
Cashflow From Investing	-44.0%	-193	-134	-157	-115	-1,046	-290	-200	-336	-289	-291	-25.00	-22.00	-38.00	-33.00	5,261	3,932	-9,317	-2,075	-41.00	-548	-
Cashflow From Financing	-69.0%	22.00	71.00	46,409	-235	-219	34,569	6,648	-146	174	259	116	36.00	46.00	-279	45,156	-514	51,105	2,261	11,682	484	-

TELA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss
Revenue	$ 58,453	$ 41,418	$ 29,463
Cost of revenue (excluding amortization of intangible assets)	17,961	13,570	10,346
Amortization of intangible assets	380	804	304
Gross profit	40,112	27,044	18,813
Operating expenses:
Sales and marketing	59,681	43,252	29,062
General and administrative	14,887	13,862	12,459
Research and development	9,619	8,937	6,743
Total operating expenses	84,187	66,051	48,264
Loss from operations	(44,075)	(39,007)	(29,451)
Other expense:
Interest expense	(5,223)	(4,051)	(3,597)
Loss on extinguishment of debt		(1,228)
Other income (expense)	2,634	(10)	(228)
Total other expense	(2,589)	(5,289)	(3,825)
Net loss	$ (46,664)	$ (44,296)	$ (33,276)
Net loss per common share, basic	$ (2.04)	$ (2.72)	$ (2.30)
Net loss per common share, diluted	$ (2.04)	$ (2.72)	$ (2.30)
Weighted average common shares outstanding, basic	22,868,663	16,267,678	14,473,213
Weighted average common shares outstanding, diluted	22,868,663	16,267,678	14,473,213
Comprehensive loss:
Net loss	$ (46,664)	$ (44,296)	$ (33,276)
Foreign currency translation adjustment	(59)	202	19
Comprehensive loss	$ (46,723)	$ (44,094)	$ (33,257)

TELA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,729	$ 42,019
Accounts receivable, net of allowances of $416 and $143	9,737	6,621
Inventory	13,162	11,792
Prepaid expenses and other assets	2,098	2,015
Total current assets	71,726	62,447
Property and equipment, net	1,984	1,682
Intangible assets, net	2,119	2,499
Right-of-use assets	1,954	1,227
Restricted cash	265
Total assets	78,048	67,855
Current liabilities:
Accounts payable	1,667	1,534
Accrued expenses and other current liabilities	15,300	10,869
Total current liabilities	16,967	12,403
Long-term debt	40,515	39,916
Other long-term liabilities	1,685	1,231
Total liabilities	59,167	53,550
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock; $0.001 par value: 200,000,000 shares authorized; 24,494,675 and 19,165,027 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	24	19
Additional paid-in capital	339,655	288,361
Accumulated other comprehensive income	91	150
Accumulated deficit	(320,889)	(274,225)
Total stockholders' equity	18,881	14,305
Total liabilities and stockholders' equity	$ 78,048	$ 67,855

About Tela Bio Inc

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

CEO	Mr. Antony Koblish
WEBSITE	telabio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	173

Tela Bio Inc Frequently Asked Questions

What is the ticker symbol for Tela Bio Inc? What does TELA stand for in stocks?

TELA is the stock ticker symbol of Tela Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tela Bio Inc (TELA)?

As of Fri Apr 26 2024, market cap of Tela Bio Inc is 109.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TELA stock?

You can check TELA's fair value in chart for subscribers.

What is the fair value of TELA stock?

You can check TELA's fair value in chart for subscribers. The fair value of Tela Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tela Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TELA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tela Bio Inc a good stock to buy?

The fair value guage provides a quick view whether TELA is over valued or under valued. Whether Tela Bio Inc is cheap or expensive depends on the assumptions which impact Tela Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TELA.

What is Tela Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TELA's PE ratio (Price to Earnings) is -2.35 and Price to Sales (PS) ratio is 1.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TELA PE ratio will change depending on the future growth rate expectations of investors.